Evidence map›Paper›PMID 40881645›Full record

ArticlePrecision oncogenomics2025

Identifying Drug Combination Strategies for

Ariane Huang, Sofia R Beer, Christopher A Eide, Brian J Druker, Jeffrey W Tyner, Jessica Leonard, Cristina E Tognon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Precision oncogenomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ariane HuangKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Sofia R BeerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Christopher A EideKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Jessica LeonardKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Cristina E TognonKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0002-4872-3078

Funding

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMLU54CA224019 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jeffrey Wallace Tyner · 2017 to 2026
$13.9M
Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemiaU01CA271412 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRIAN J DRUKER, Paul D Piehowski · 2022 to 2026
$5.8M
Mechanisms of venetoclax combination activity in acute myeloid leukemiaR01CA262758 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Stephen E Kurtz, Jeffrey Wallace Tyner · 2021 to 2026
$2.1M
NCI NIH HHS R01 CA262758NCI NIH HHS U01 CA271412NCI NIH HHS U54 CA224019
6 · The paper itself

Abstract

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) are a class of fusion protein-driven, poor prognosis leukemias. Leukemias harboring FGFR1 fusions have previously been referred to as 8p11.2 myeloproliferative syndrome (EMS) or stem cell leukemia/lymphoma (SCLL) and are currently referred to as Myeloid/lymphoid neoplasms with FGFR1 rearrangement based on the most recent WHO classification system. To identify new therapeutic options for MLN-TK patients, we evaluated clinical and

Identifiers

PMID40881645
PMCPMC12379768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.